The risk of therapy duplication with OTC and prescription PPIs can be lowered with an innovative, multi-faceted, and intentional approach by pharmacy teams and prescribers.
Khemraj Hirani, PhD, RPh, MBA, MPharm, RAC, CIP, CCRP
Advertisement
Articles by Khemraj Hirani, PhD, RPh, MBA, MPharm, RAC, CIP, CCRP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
3
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
4
Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings
5
